BioLine RX Ltd ADR buy tamam
Zusammenfassung
Diese Einschätzung wurde am 03.06.19 mit einem Endkurs von 73,06 € beendet. Stark abwärts ging es für die BUY Einschätzung von tamam zu BioLine RX Ltd ADR mit einer Rendite von -67,57 %. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
BioLine RX Ltd ADR | - | - | - | - |
iShares Core DAX® | -3,94 % | -2,63 % | 10,01 % | 11,95 % |
iShares Nasdaq 100 | -3,61 % | -9,28 % | 20,67 % | 35,71 % |
iShares Nikkei 225® | -4,51 % | -6,95 % | 5,24 % | 2,60 % |
iShares S&P 500 | -2,61 % | -4,40 % | 20,18 % | 37,82 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion BioLine RX Ltd ADR diskutieren
BioLineRx in partnership with Novartis and collaboration with Roche
BioLineRx might be one of the best biotech values in the stock market, as it has a promising
pipeline, a cash-rich balance sheet and a low burn rate.
This stock dropped many weeks ago when the company announced a secondary offering, but it has since built a strong base and could be poised to rebound.
The pipeline is promising with its lead candidate BL-8040 being a potential blockbuster with multiple indications.
A leading biotech fund and Novartis have taken a major stake in this company and analyst price targets of $3 to $4 per share, suggests significant upside.
BioLineRx (NASDAQ:BLRX) initiated with Outperform rating and $3 (186% upside) price target by Oppenheimer.